A phase III open label randomized study to compare the efficacy of lenalidomide-rituximab vs bendamustine-rituximab in treatment naive follicular lymphoma.

被引：2
|
作者：
Paikaray, Susanta Kumar
Gogia, Ajay
Kumar, Lalit
Sharma, Atul
Biswas, Ahitagni
Sharma, Mehar C.
Thulker, Sanjay
Kumar, Rakesh
Vishnubhatla, Sreenivas
Mallick, Saumyaranjan
机构：
[1] All India Inst Med Sci, New Delhi, India
[2] All India Inst Med Sci, Delhi, India
[3] All India Inst Med Sci, Dept Biostat, New Delhi, India
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e19552
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19552
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A Phase III open-label randomized study to compare the efficacy of lenalidomide-rituximab with bendamustine-rituximab in treatment-naïve follicular lymphoma
    Paikaray, Sushant Kumar
    Gogia, Ajay
    Kumar, Lalit
    Sharma, Atul
    Biswas, Ahit Agni
    Vishnubhatla, Sreeniwas
    Mallick, Soumya
    INDIAN JOURNAL OF CANCER, 2023, 60 (04) : 501 - 504
  • [2] Safety and Efficacy of Bendamustine-Rituximab in Treatment Naive Symptomatic Follicular Lymphoma: An Institutional Analysis
    Gogia, Ajay
    Kumar, Sudhir
    Kumar, Lalit
    Sharma, Atul
    Mallick, Soumya
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2021, 37 (01) : 169 - 170
  • [3] Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial
    Kersten, Marie Jose
    Dreyling, Martin
    Linton, Kim M.
    Chitu, Dana
    Tonino, Sanne
    Kap, Marcel
    Liu, Roberto D.
    Chamuleau, Martine E. D.
    Visser, Hein P. J.
    De Jongh, Eva
    Marijt, Erik Waf
    Leijs, Maria B. L.
    Bilgin, Yavuz M.
    Duerig, Jan
    McKay, Pamela
    Snijders, Tjeerd J. F.
    Pettitt, Andrew
    Minnema, Monique C.
    Prange-Krex, Gabriele
    Cuijpers, Maria
    Boehmer, Lara H.
    Tick, Lidwine W.
    Florschuetz, Axel
    Silbermann, Matthijs
    Fijnheer, Rob
    Beeker, Aart
    Tolboom, Nelleke
    Mitea, Cristina
    Arens, Anne I. J.
    Zwezerijnen, Gerben J. C.
    Klapper, Wolfram
    Coupland, Sarah E.
    de Jong, Daphne
    Doorduijn, Jeanette K.
    Zijlstra, Josee M.
    BLOOD, 2022, 140 : 2283 - 2285
  • [4] Safety and Efficacy of Bendamustine-Rituximab in Treatment Naïve Symptomatic Follicular Lymphoma: An Institutional Analysis
    Ajay Gogia
    Sudhir Kumar
    Lalit Kumar
    Atul Sharma
    Soumya Mallick
    Indian Journal of Hematology and Blood Transfusion, 2021, 37 : 169 - 170
  • [5] RELEVANCE: Phase III randomized study of lenalidomide plus rituximab (R2) versus chemotherapy plus rituximab, followed by rituximab maintenance, in patients with previously untreated follicular lymphoma.
    Fowler, Nathan Hale
    Morschhauser, Franck
    Feugier, Pierre
    Bouabdallah, Reda
    Tilly, Herve
    Palomba, Maria Lia
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study
    Gordon, Max J.
    Feng, Lei
    Strati, Paolo
    Lee, Hun Ju
    Hagemeister, Fredrick B.
    Westin, Jason R.
    Samaniego, Felipe
    Marques-Piubelli, Mario L.
    Vega Vazquez, Francisco
    Parra Cuentas, Edwin R.
    Solis-Soto, Luisa M.
    Ma, Wencai
    Wang, Jing
    Claret, Linda
    Averill, Barbara
    Ibanez, Karina
    Fayad, Luis E.
    Flowers, Christopher R.
    Green, Michael R.
    Davis, R. Eric
    Neelapu, Sattva S.
    Fowler, Nathan H.
    Nastoupil, Loretta J.
    CANCER, 2024, 130 (06) : 876 - 885
  • [7] inMIND: A phase 3 study of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab for relapsed/refractory follicular or marginal zone lymphoma.
    Sehn, Laurie Helen
    Hubel, Kai
    Luminari, Stefano
    Salar, Antonio
    Wahlin, Bjorn E.
    Gopal, Ajay K.
    Bonnet, Christophe Marc
    Paneesha, Shankara
    Trneny, Marek
    Mashegu, Hafsat Umar
    Lihou, Christine Francis
    Li, Di
    Scholz, Christian W.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [8] Safety and Efficacy of Ibrutinib in Combination with Rituximab and Lenalidomide in Previously Untreated Subjects with Follicular and Marginal Zone Lymphoma: An Open Label, Phase II Study
    Nastoupil, Loretta J.
    Lee, Hun Ju
    Hagemeister, F. B.
    Westin, Jason R.
    Samaniego, Felipe
    Feng, Lei
    John, Jiffin
    Forbes, Sheryl G.
    Fayad, Luis E.
    Green, Michael R.
    Davis, R. Eric
    Neelapu, Sattva S.
    Fowler, Nathan H.
    BLOOD, 2018, 132
  • [9] Rituximab-Bendamustine in First Line Treatment of Patients with Follicular Lymphoma. Results of Prospective Multicenter Study
    Ekaterina, Nesterova
    Kravchenko, Sergey K.
    Kovrigina, Alla M.
    Plastinina, Lubov V.
    Mangasarova, Yana K.
    Gorenkova, Liliya
    Vorobyev, Vladimir
    Mariin, Dmitriy
    Baryakh, Elena A.
    Polyakov, Yuriy
    Zeynalova, Pervin
    Volodicheva, Elena
    Glonina, Nataliya
    Savchenko, Valeriy G.
    BLOOD, 2017, 130
  • [10] Phase III Randomized AUGMENT Study of Lenalidomide/Rituximab vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
    Gribben, J.
    Trneny, M.
    Izutsu, K.
    Fowler, N. H.
    Hong, X.
    Zhu, J.
    Zhang, H.
    Offner, F.
    Scheliga, A.
    Nowakowski, G.
    Pinto, A.
    Re, F.
    Fogliatto, L. M.
    Scheinberg, P.
    Flinn, I.
    Moreira, C.
    Liu, D.
    Kalambakas, S.
    Fustier, P.
    Wu, C.
    Leonard, J. P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 79 - 79
12345